Boston Scientific won FDA approval for its Vercise deep brain stimulation system.
The system is indicated for treating symptoms of Parkinson’s disease by delivering adaptable stimulation of a region in a patient’s brain through implanted leads, which are powered by an implantable pulse generator device.
Vercise was developed using cochlear implant technology as a foundation. The battery-powered device is rechargeable and the battery can last up to 15 years or more.
The first Vercise system commercial implant in the U.S. will take place at the University of Minnesota Medical Center, the company said.